# Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC

> **NCT06700382** · — · RECRUITING · sponsor: **Shu Wang** · enrollment: 1166 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT06700382
- **Lead sponsor:** Shu Wang
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2019-01-01
- **Primary completion:** 2031-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 1166 (ESTIMATED)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06700382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06700382, "Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06700382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*